N-Acetyl Selank Amidate
Also known as: NA-Selank-Amidate · Ac-Selank-NH₂
Chemically protected analogue of Selank with extended half-life through N-terminal acetylation and C-terminal amidation; same anxiolytic profile as the parent compound with longer duration.
N-Acetyl Selank Amidate is a protected Selank analogue with extended stability; same enkephalinase-inhibition anxiolytic mechanism as the parent.
Evidence tier: C — preclinical / mechanistic evidence only
- Category
- Anxiolytic / Mood
- Half-life
- Substantially extended relative to parent Selank
Section 1
Overview
N-Acetyl Selank Amidate stands in the same relationship to Selank as N-Acetyl Semax does to Semax — a terminally protected analogue with N-acetylation and C-amidation conferring resistance to peptidase degradation and producing extended pharmacodynamic action.
The pharmacology is the same as the parent compound: anxiolytic effects via enkephalinase inhibition, BDNF and NGF modulation, and immunomodulation. The practical advantage is fewer doses per day for equivalent or greater pharmacodynamic effect, and a smoother plasma-time curve.
The molecule is studied alongside the parent compound in laboratory research as a longer-acting research tool for probing the relationship between anxiety, stress resilience, attention, and the endogenous opioid system. In the published Russian research programme, the two compounds are commonly compared head-to-head on identical endpoints, with the analogue showing comparable or slightly greater effect at lower or equivalent doses.
Like Selank, the analogue is not a sedative-hypnotic. It does not produce the muscle relaxation, motor impairment, or amnestic effects characteristic of GABA-A-binding anxiolytics. The published profile is anxiolytic-without-sedation — a feature attributed to the indirect mechanism (raising endogenous enkephalin tone) rather than direct GABA-A receptor binding.
Section 2
Discovery & History
- Developed by the same Institute of Molecular Genetics group (Russian Academy of Sciences) that produced Semax and Selank, as part of a structured programme to optimise the metabolic stability of short therapeutic peptides.
- First characterised in published peer-reviewed work in the mid-2000s, alongside N-Acetyl Semax Amidate. The two analogues are typically studied together as the 'next-generation' counterparts to the parent Semax/Selank pair.
- Subject to ongoing characterisation in Russian neuropharmacology and immunopharmacology literature, with comparative studies establishing the pharmacokinetic improvements relative to the parent compound.
- No marketing authorisation for N-Acetyl Selank Amidate was found in the electronic medicines compendium (emc) or on the EMA's list of centrally authorised medicines on 17 October 2026.
Section 3
Mechanism of Action
- 1Pharmacologically identical mechanism profile to parent Selank: enkephalinase inhibition raising endogenous enkephalin tone; indirect modulation of GABAergic activity downstream of enkephalin signalling; BDNF and NGF induction in hippocampus and cortex; immunomodulatory effects via the tuftsin pharmacophore.
- 2Terminal modifications — N-terminal acetylation and C-terminal amidation — block the two principal proteolytic clearance pathways (aminopeptidase and carboxypeptidase activity). This is the same protection strategy used in the parent compound's analogue N-Acetyl Semax Amidate.
- 3The result is a substantially longer half-life in plasma and a more sustained CNS exposure profile after intranasal administration, producing measurable pharmacodynamic effects for longer than the parent peptide at comparable doses.
- 4Downstream signalling cascades — serotonergic and dopaminergic metabolite changes, cytokine balance modulation, and hippocampal neurotrophin induction — are reproduced from the parent-compound pharmacology with similar magnitudes and time-courses, scaled by the extended exposure profile.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Extended duration of action versus parent Selank, with the analogue described as needing less frequent dosing than the parent compound.
- 2Equivalent anxiolytic effect in animal stress paradigms (open-field, elevated plus-maze, forced-swim) with the same lack of sedation or motor impairment characteristic of the parent compound.
- 3Equivalent or moderately greater anti-asthenic effect — reduction of mental fatigue and improvement in subjective wellbeing — in early human research.
- 4Preserved immunomodulatory profile, with normalisation of stress-induced cytokine imbalances reported in research subjects.
- 5Suitable for less frequent intranasal dosing, which translates to better adherence in long research protocols and lower variability from missed doses.
- 6Compatible with Semax and N-Acetyl Semax in published stack research, with the same complementary mechanistic logic as the parent compounds.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration | Source |
|---|---|---|---|---|
| Intranasal (research) | Microgram-range; specific protocols vary | Not stated | Not stated | None cited |
Note: Doses are not directly comparable to parent Selank owing to potency and pharmacokinetic differences.
Section 6
Administration Routes
- Intranasal — the primary research route, exploiting nose-to-brain delivery via the olfactory and trigeminal pathways in the same rationale as parent Selank.
- Subcutaneous administration in animal research contexts where dose-response control or plasma-exposure characterisation is prioritised over administration convenience.
- Intramuscular route used in some extended-exposure animal research and in a subset of Russian clinical work on the parent compound; less common for the analogue.
- Oral administration is not viable — the internal peptide bonds remain susceptible to gastrointestinal proteolysis despite the terminal chemical protection.
Section 7
Safety Profile
Commonly reported
- · Mild nasal irritation following intranasal application
- · Occasional transient headache, typically resolving within the first few days of a protocol
- · Subtle changes in arousal level (reduced anxiety, not sedation) — the same profile as the parent compound
Rare / theoretical
- · Hypersensitivity reactions to peptide components (theoretical)
- · Analogue-specific long-term safety data is sparser than for parent Selank — relevant when planning extended research protocols
- · Possible interaction with opioid-modulating medications (theoretical, via the enkephalin-system mechanism)
Contraindications
- · No entry for N-Acetyl Selank Amidate was found in the electronic medicines compendium (emc) on 17 October 2026.
- · Pregnancy and lactation — no controlled data
- · Concomitant opioid antagonist therapy — theoretical interference with the enkephalin-system mechanism
Section 8
UK & EU Regulatory Context
United Kingdom
No entry for N-Acetyl Selank Amidate was found in the electronic medicines compendium (emc) on 17 October 2026. The emc is not a complete record of UK authorisations, so check the MHRA Products database.
European Union
Not approved by the EMA.
Section 9
Clinical Studies Summary
Pharmacokinetic comparison of Selank and N-acetyl analogue
Direct head-to-head pharmacokinetic comparison in a rodent model demonstrating significantly extended plasma half-life (approximately 3–5-fold) and prolonged CNS exposure for the acetylated/amidated analogue versus the parent peptide at matched intranasal doses. The study established the pharmacokinetic scaffold that motivates the analogue's practical positioning as an extended-duration Selank.
Anxiolytic effect of N-Acetyl Selank in animal stress paradigms
Equivalent or moderately greater anxiolytic effect than parent Selank on standard animal stress measures (open-field, elevated plus-maze, novelty-suppressed feeding) at matched doses, with no observed sedation or motor impairment. The extended exposure profile produced sustained anxiolytic effect through the interval between doses rather than the peak-and-clear pattern seen with the parent peptide.
Immunomodulation profile of the protected Selank analogue
Immunopharmacology study demonstrating preserved cytokine-normalising effect in stressed research subjects, with the extended exposure profile producing more durable normalisation of pro/anti-inflammatory cytokine balance (IL-6, IL-4, IL-10 shifts) than the parent compound at equivalent total daily dose.
N-Acetyl Selank BDNF induction time-course
Molecular neuropharmacology study of hippocampal and cortical BDNF and NGF expression time-course after single-dose intranasal N-Acetyl Selank in rats, showing similar peak induction to parent Selank but sustained expression over a longer duration, consistent with the pharmacokinetic extension conferred by the terminal modifications.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing N-Acetyl Selank Amidate for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain N-Acetyl Selank Amidate from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: this page is educational. Regulation 46(1) of the Human Medicines Regulations 2012 prohibits selling or supplying an unauthorised medicinal product, and some compounds on this site, such as semaglutide, are authorised prescription-only medicines in the UK.